Ikekubo K, Hino M, Ito H, Hirao K, Ueshima M, Tanaka T, Kobayashi H, Ishihara T, Kurahachi H
Department of Nuclear Medicine, Kobe City General Hospital.
Kaku Igaku. 2000 Jul;37(4):349-57.
Brain metastases from differentiated thyroid carcinoma are extremely rare and carry a poor prognosis. We describe here clinical details of 7 cases of brain metastases from papillary thyroid carcinoma. Of 153 patients with metastases from differentiated thyroid carcinoma (papillary in 123, follicular in 30) treated at our institution between 1981 and 1999, 7 patients (4.6%) had brain metastases. Histologically, the primary tumor was papillary carcinoma in all 7 cases. Four were males and 3 were females. The median age at first diagnosis of distant metastases was 63 yr (range, 47-76 yr). Of these patients, one had brain metastases only and six had metastases to the lungs as well. Five of these patients were treated with 131I. Three of these 5 patients had marked uptake in the metastases (131I positive) on post-therapy 131I scans and another 2 patients had no significant activity (131I negative) in both pulmonary and brain metastatic lesions. One of 3 patients with 131I positive lesions had intense activity in the brain tumor, but no uptake in multiple pulmonary metastatic tumors. In a patient with 131I positive brain metastases, the tumors progressed rapidly after 131I therapy. In another one patient, acute hemorrhage of the tumor occurred four days after 131I therapy, requiring surgical removal. Loner case of 131I negative 2 patients was treated with radiosurgery (gamma-knife) and complete reduction in tumor volume was observed. On the other hand, one of 2 patients receiving no 131I therapy had radiosurgery (x-knife) and remaining one received conventional external radiation and chemotherapy for small solitary brain and pulmonary metastatic tumors. These therapeutic interventions were useful in both cases. The mean length of survival after the development of brain metastases in the five patients who died of the disease was 30 months. One patient treated with x-knife has been alive at 21 months and another one who has 131I uptake in the brain tumor without uptake in lung lesions has been alive 15 months after diagnosis of brain metastasis. These results indicate that it is important to detect brain metastasis by imaging techniques and Tg measurements and give treatment as early as possible since the brain is the third most common distant metastatic site and the prognosis is poor.
分化型甲状腺癌脑转移极为罕见,预后较差。我们在此描述7例甲状腺乳头状癌脑转移的临床细节。1981年至1999年间在我们机构接受治疗的153例分化型甲状腺癌转移患者(其中乳头状癌123例,滤泡状癌30例)中,7例(4.6%)发生了脑转移。组织学检查显示,所有7例患者的原发肿瘤均为乳头状癌。男性4例,女性3例。首次诊断远处转移时的中位年龄为63岁(范围47 - 76岁)。这些患者中,1例仅有脑转移,6例同时伴有肺转移。其中5例患者接受了131I治疗。这5例患者中,3例在治疗后131I扫描时转移灶有明显摄取(131I阳性),另外2例患者的肺和脑转移灶均无明显活性(131I阴性)。3例131I阳性病变患者中有1例脑肿瘤有强烈活性,但多个肺转移瘤无摄取。1例131I阳性脑转移患者在131I治疗后肿瘤进展迅速。另1例患者在131I治疗4天后肿瘤发生急性出血,需手术切除。2例131I阴性患者中的1例接受了放射外科治疗(伽玛刀),观察到肿瘤体积完全缩小。另一方面,2例未接受131I治疗的患者中,1例接受了放射外科治疗(X刀),另1例因脑和肺小的孤立转移瘤接受了常规外照射和化疗。这些治疗干预在两种情况下均有效。5例死于该病的患者发生脑转移后的平均生存时间为30个月。1例接受X刀治疗的患者已存活21个月,另1例脑肿瘤有131I摄取但肺部病变无摄取的患者在诊断脑转移后已存活15个月。这些结果表明,通过影像学检查和Tg测量检测脑转移并尽早给予治疗很重要,因为脑是第三常见的远处转移部位且预后较差。